Osteoarthritis Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017

GlobalData, May 2011, Pages: 92

Osteoarthritis Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, “Osteoarthritis Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global osteoarthritis pain market. The report identifies the key trends shaping and driving the global osteoarthritis pain market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global osteoarthritis pain sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global Osteoarthritis pain therapeutics market was valued at $4.9 billion in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 3.3% over the next seven years, to reach $6.1 billion by 2017. This slow growth is primarily attributed to a low treatment seeking behavior, disease awareness and usage of generic drugs. The current competitive landscape consists of branded, generic and off-label drugs.

Scope

The report provides information on the key drivers and challenges of the osteoarthritis pain market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) osteoarthritis pain market revenues data from 2005 to 2010, forecast for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as COX-II inhibitors, TRPV antagonists, Opiod receptor agonists, anti NGF mAB and CB-2 agonists.
- Analysis of the current and future competition in the seven key countries osteoarthritis pain market. Key market players covered are Abbott Laboratories, Adolor Corporation, Cephalon, Inc., Endo Pharmaceuticals, Elite Pharmaceuticals, Glenmark Pharmaceuticals, Grunenthal GMBH, Johnson & Johnson Pharmaceuticals Ltd., Pfizer, Inc., SantaSolve AS, and Sanofi-Aventis.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the osteoarthritis pain therapeutics market.
- Analysis of key recent licensing and partnership agreements in osteoarthritis pain market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global osteoarthritis pain market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global osteoarthritis pain market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global osteoarthritis pain market landscape? – Identify, understand and capitalize.

1 Table of contents
1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 OA Pain Therapeutics - Introduction
2.1 Disease Overview
2.1.1 OA Pain
2.2 Epidemiology
2.3 Etiology and Pathophysiology
2.3.1 Progression of the Disease
2.4 Signs and Symptoms
2.5 Diagnosis
2.5.1 Commonly Used Diagnosis Tests
2.6 Treatment and Management Options
2.7 Pipeline Report Guidance
3 OA PainTherapeutics - Market Characterization
3.1 OA Pain Therapeutics Market Size (2005-2010) – Global
3.2 OA Pain Therapeutics Market Forecast (2010-2017) – Global
3.3 OA Pain Therapeutics Market Size (2005-2010) – The US
3.4 OA Pain Therapeutics Market Forecast (2010-2017) – The US
3.5 OA Pain Therapeutics Market Size (2005-2010) – France
3.6 OA Pain Therapeutics Market Forecast (2010-2017) – France
3.7 OA Pain Therapeutics Market Size (2005-2010) – Germany
3.8 OA Pain Therapeutics Market Forecast (2010-2017) – Germany
3.9 OA Pain Therapeutics Market Size (2005-2010) – Italy
3.10 OA pain Therapeutics Market Forecast (2010-2017) – Italy
3.11 OA Pain Therapeutics Market Size (2005-2010) – Spain
3.12 OA Pain Therapeutics Market Forecast (2010-2017) – Spain
3.13 OA Pain Therapeutics Market Size (2005-2010) – The UK
3.14 OA Pain Therapeutics Market Forecast (2010-2017) – The UK
3.15 OA Pain Therapeutics Market Size (2005-2010) – Japan
3.16 OA Pain Therapeutics Market Forecast (2010-2017) – Japan
3.17 Drivers and Barriers for the OA Pain Therapeutics Market
3.17.1 Drivers for the OA Pain Therapeutics Market
3.17.2 Barriers for the OA Pain Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway
4 OA Pain Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the OA Pain Therapeutics Market
4.3.1 Celebrex (celecoxib)
4.3.2 Voltaren Gel (diclofenac sodium)
4.3.3 Morphine
4.3.4 Hyalgan (sodium hyaluronate)
4.4 Key Takeaway
5 OA Pain Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 OA Pain Therapeutics Pipeline – Pipeline by Phases of Development
5.3.1 OA Pain Therapeutics – Regulatory Filed Products
5.3.2 OA Pain Therapeutics – Phase III Pipeline
5.3.3 OA Pain Therapeutics – Phase II Pipeline
5.3.4 OA Pain Therapeutics – Phase I Pipeline
5.3.5 OA Pain Market – Discovery and Pre-Clinical Pipeline
5.3.6 Technology Trends Analytic Framework
5.4 OA Pain Therapeutics Market – Clinical Pipeline by Mechanism of Action
5.5 OA Pain Therapeutics – Promising Drugs Under Clinical Development
5.6 Molecule Profile for Promising Drugs Under Clinical Development
5.6.1 2PX
5.6.2 Nucynta ER (tapentadol)
5.7 Key Takeaway
6 OA Pain Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (the US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in OA pain Therapeutics Clinical Trials
7 Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 OA Pain Therapeutics: Implications for Future Market Competition
8 OA Pain Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Abbott Laboratories
8.2.2 Adolor Corporation
8.2.3 Cephalon, Inc.
8.2.4 Endo Pharmaceuticals
8.2.5 Elite Pharmaceuticals
8.2.6 Glenmark Pharmaceuticals
8.2.7 Grunenthal GmbH
8.2.8 Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
8.2.9 Pfizer, Inc.
8.2.10 Sanofi
8.2.11 Other Companies in the OA Pain Therapeutics Market
9 OA Pain Therapeutics - Licensing and Partnership Deals
10 OA Pain Therapeutics - Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: OA Pain Therapeutics Market, Global, Revenue ($bn), 2005–2010
Table 2: OA Pain Therapeutics Market, Global, Forecast ($bn), 2010–2017
Table 3: OA Pain Therapeutics Market, The US, Revenue ($bn), 2005–2010
Table 4: OA Pain Therapeutics Market, The US, Forecasts ($bn), 2010–2017
Table 5: OA Pain Therapeutics Market, France, Revenue ($m), 2005–2010
Table 6: OA Pain Therapeutics Market, France, Forecasts ($m), 2010–2017
Table 7: OA Pain Therapeutics Market, Germany, Revenue ($m), 2005–2010
Table 8: OA Pain Therapeutics Market, Germany, Forecasts ($m), 2010–2017
Table 9: OA Pain Therapeutics Market, Italy, Revenue ($m), 2005–2010
Table 10: OA Pain Therapeutics Market, Italy, Forecasts ($m), 2010–2017
Table 11: OA Pain Therapeutics Market, Spain, Revenue ($m), 2005–2010
Table 12: OA Pain Therapeutics Market, Spain, Forecasts ($m), 2010–2017
Table 13: OA Pain Therapeutics Market, The UK, Revenue ($m), 2005–2010
Table 14: OA Pain Therapeutics Market, The UK, Forecasts ($m), 2010–2017
Table 15: OA Pain Therapeutics Market, Japan, Revenue ($m), 2005–2010
Table 16: OA Pain Therapeutics Market, Japan, Forecasts ($m), 2010–2017
Table 17: OA Pain Therapeutics – Regulatory Filed Products, 2011
Table 18: OA Pain Therapeutics – Phase III Pipeline, 2011
Table 19: OA Pain Therapeutics – Phase II Pipeline, 2011
Table 20: OA Pain Therapeutics – Phase I Pipeline, 2011
Table 21: OA Pain Therapeutics – Discovery and Pre-Clinical Pipeline, 2011
Table 22: OA Pain Therapeutics – Most Promising Drugs Under Clinical Development, 2011
Table 23: OA Pain Therapeutics – Clinical Trials by Country, 2011
Table 24: OA Pain Therapeutics – Clinical Trials by Phase, 2011
Table 25: OA Pain Therapeutics – Clinical Trials by Status, 2011
Table 26: OA Pain Therapeutics, Overall Sponsors
Table 27: OA Pain Therapeutics, Most Prominent Sponsors
Table 28: OA Pain Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 29: Acura Pharmaceuticals – Pain Management, Pipeline, 2011
Table 30: Abbott Laboratories – Deals, 2009-2011
Table 31: OA Pain Therapeutics, Adolor Corporation, Pain Management Pipeline, 2011
Table 32: Adolor Corporation, Deals, 2009-2011
Table 33: OA Pain Therapeutics, Cephalon, Inc., OA pain Therapeutics Pipeline, 2011
Table 34: Cephalon, Inc., Deals, 2009-2011
Table 35: Endo Pharmaceuticals, Pain Management Therapeutic Pipeline, 2011
Table 36: Endo Pharmaceuticals, Deals, 2009-2011
Table 37: OA Pain Therapeutics, Elite Pharmaceuticals Pain Management Pipeline, 2011
Table 38: Elite Pharmaceuticals OA Pain Pipeline, 2011
Table 39: Elite Pharmaceuticals, Deals, 2009-2011
Table 40: Glenmark Pharmaceuticals, OA Pain Pipeline, 2011
Table 41: Glenmark Pharmaceuticals, Deals, 2009-2011
Table 42: Grunenthal GMBH, Pain Management Pipeline, 2011
Table 43: Grunenthal GmbH – Deals, 2009-2011
Table 44: Johnson & Johnson Pharmaceutical R&D L.L.C., OA Pain Management Pipeline, 2011
Table 45: J&JPRD, Deals, 2009-2011
Table 46: Pfizer, Pain Management Pipeline, 2011
Table 47: Pfizer, OA Pain Pipeline, 2011
Table 48: Pfizer, Inc., Deals, 2009-2011
Table 49: OA Pain Therapeutics, Sanofi Pain Management Pipeline, 2011
Table 50: Sanofi, Deals, 2009-2011
Table 51: OA Pain Therapeutics Market – Future Players
Table 52: Licensing and Partnership Deals, 2008-2011

1.2 List of Figures
Figure 1: Osteoarthritis of the Knee
Figure 2: Osteoarthritis of the Knee
Figure 3: Osteoarthritis of the Hand, Heberden’s Nodes
Figure 4: Osteoarthritis of the Hand, Bouchard’s Nodes
Figure 5: Osteoarthritis of the Hip
Figure 6: OA Pain Pathophysiology
Figure 7: OA Pain Pathophysiology
Figure 8: OA Pain Pathophysiology
Figure 9: OA Pain Pathophysiology
Figure 10: OA Pain Pathophysiology
Figure 11: OA Pain, Treatment Pattern
Figure 12: OA Pain Therapeutics Market, Global, Revenue ($bn), 2005–2010
Figure 13: OA Pain Therapeutics Market, Global, Forecast ($bn), 2010–2017
Figure 14: OA Pain Therapeutics Market, The US, Revenue ($bn), 2005–2010
Figure 15: OA Pain Therapeutics Market, The US, Forecast ($bn), 2010–2017
Figure 16: OA Pain Therapeutics Market, France, Revenue ($m), 2005–2010
Figure 17: OA Pain Therapeutics Market, France, Forecast ($m), 2010–2017
Figure 18: OA Pain Therapeutics Market, Germany , Revenue ($m), 2005–2010
Figure 19: OA Pain Therapeutics Market, Germany, Forecast ($m), 2010–2017
Figure 20: OA Pain Therapeutics Market, Italy, Revenue ($m), 2005–2010
Figure 21: OA Pain Therapeutics Market, Italy, Forecast ($m), 2010–2017
Figure 22: OA Pain Therapeutics Market, Spain, Revenue ($m), 2005–2010
Figure 23: OA Pain Therapeutics Market, Spain, Forecast ($m), 2010–2017
Figure 24: OA Pain Therapeutics Market, The UK, Revenue ($m), 2005–2010
Figure 25: OA Pain Therapeutics Market, The UK, Forecast ($m), 2010–2017
Figure 26: OA Pain Therapeutics Market, Japan, Revenue ($m), 2005–2010
Figure 27: OA Pain Therapeutics Market, Japan, Forecast ($m), 2010–2017
Figure 28: Opportunity and Unmet Need in the OA Pain Therapeutics Market,2010
Figure 29: OA Pain Therapeutics – Strategic Competitor Assessment, 2011
Figure 30: OA Pain Therapeutics – Pipeline by Phase of Development, 2011
Figure 31: OA Pain Therapeutics – Technology Trends Analytics Framework, 2011
Figure 32: OA Pain Therapeutics – Technology Trends Analytics Framework – Description, 2011
Figure 33: OA Pain Therapeutics – Pipeline by Mechanism of Action, 2011
Figure 34: OA Pain Therapeutics – Clinical Trials by Country, 2011
Figure 35: OA Pain Therapeutics – Clinical Trials by Phase, 2011
Figure 36: OA Pain Therapeutics – Clinical Trials by Status, 2011
Figure 37: OA Pain Therapeutics – Overall Sponsors, 2011
Figure 38: OA Pain Therapeutics – Prominent Sponsors, 2011
Figure 39: OA Pain Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2011
Figure 40: OA Pain Therapeutics Market, Drivers and Restraints, 2011
Figure 41: Implications for Future Market Competition in the OA pain Market, 2011
Figure 42: OA Pain Therapeutics Market – Pipeline by Company, 2011
Figure 43: Market Forecasting Model

“Osteoarthritis (OA) Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017” is an essential source of information and analysis on the global osteoarthritis pain market. The report identifies the key trends shaping and driving the global osteoarthritis pain market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global osteoarthritis pain sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis. the authors estimate that the global Osteoarthritis pain therapeutics market was valued at $4.9 billion in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 3.3% over the next seven years, to reach $6.1 billion by 2017. This slow growth is primarily attributed to a low treatment seeking behavior, disease awareness and usage of generic drugs. The current competitive landscape consists of branded, generic and off-label drugs.

OA Pain Therapeutics Market is forecast to Show Slow Growth until 2017

The author estimates that the global osteoarthritis (OA) pain therapeutics market was valued at $4.9 billion in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 3.3% over the next seven years, to reach $6.1 billion by 2017. This slow growth is primarily attributed to low levels of treatment-seeking behavior, disease awareness and the usage of generic drugs. The current competitive landscape consists of branded, generic and off-label drugs.

Changing Future Landscape of the OA Pain Therapeutics Market

Abbott Laboratories, Adolor Corporation, Cephalon, Inc., Endo Pharmaceuticals, Elite Pharmaceuticals, Glenmark Pharmaceuticals, Grunenthal GMBH, Johnson & Johnson Pharmaceuticals Ltd., Pfizer, Inc., SantaSolve AS, and Sanofi-aventis are going to be the key players in the OA pain market. The authors has profiles of all these companies as they hold important pipeline drugs in late stage development for OA Pain treatment.
The existing market landscape remains competitive, because the treatment of OA Pain relies on established, older therapies like non-steroidal anti-inflammatory drugs (NSAIDS), opioids, and Cyclooxygenase-II (COX-II) inhibitors. The market scenario is expected to change after the launch of new disease modifying therapies such as TRPV1, 3 antagonists, aggrecanase inhibitors, GABA B receptor modulators, inducible nitric oxide synthase (iNOS) inhibitor, platelet secreted growth factors, and Anti NGF mAB.

Abbott Laboratories
Adolor Corporation
Cephalon, Inc.
Endo Pharmaceuticals
Elite Pharmaceuticals
Glenmark Pharmaceuticals
Grunenthal GmbH
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Pfizer, Inc.
Sanofi

Customers who bought this item also bought

• The Future of Pain Management Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Generic Competition Creates Challenges
• Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014
• Neuropathic Pain: Treatments and Prescribing Practices - A Global Survey 2009
• Global Musculoskeletal Pain Drug Pipeline Capsule - 2012
• Epidemiology: Chronic Lower Back Pain - Millions will continue to be out of work over the next decade
• Endometriosis - Global Strategic Business Report
• Diabetes Diagnostics - Global Strategic Business Report
• Science of Pain
• Overactive Bladder (OAB) Therapeutics - Global Strategic Business Report
• Global Osteoporosis Therapeutics Market: Market Forecast, Patient Flow,Competitive Landscape, and Pipeline Analysis